Samsung Group And Quintiles To Form A Bio-Pharmaceutical Venture

Samsung says it will form a joint venture with a U.S. company as the South Korean conglomerate expands further into biopharmaceuticals.

Samsung said in a release Friday that three of its group companies are partnering with clinical research company Quintiles Transnational Corp. of the United States in a venture with initial capital of 300 billion won ($266 million).

The Samsung companies, which include conglomerate flagship Samsung Electronics Co., will own 90 percent of the venture. Durham, North Carolina-based Quintiles will take 10 percent.

The Washington Post

Read The Full Article

Previous Next

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.